Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Genmab A/S - American Depositary Shares
(NQ:
GMAB
)
29.54
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S - American Depositary Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
October 22, 2023
From
Seagen Inc.
Via
Business Wire
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
↗
October 20, 2023
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
October 18, 2023
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
What 13 Analyst Ratings Have To Say About Genmab
↗
October 13, 2023
Via
Benzinga
Expert Ratings for Genmab
↗
September 26, 2023
Via
Benzinga
Analyst Expectations for Genmab's Future
↗
September 05, 2023
Via
Benzinga
Analyst Expectations for Genmab's Future
↗
August 15, 2023
Via
Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
↗
September 26, 2023
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.
Via
InvestorPlace
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
September 25, 2023
From
Genmab A/S
Via
Business Wire
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
September 25, 2023
From
Genmab A/S
Via
Business Wire
12 Analysts Have This to Say About Genmab
↗
July 24, 2023
Via
Benzinga
Where Genmab Stands With Analysts
↗
June 26, 2023
Via
Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
↗
September 14, 2023
The biotech stock's lead therapy is looking at some competition.
Via
The Motley Fool
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
↗
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Via
Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
↗
September 05, 2023
Zai Lab's shares benefited from positive clinical trial news.
Via
The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
↗
September 05, 2023
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on...
Via
Benzinga
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
September 04, 2023
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
September 04, 2023
From
Genmab A/S
Via
Business Wire
The 3 Most Promising Biotech Stocks to Own Now
↗
August 31, 2023
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
↗
August 24, 2023
Via
Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
↗
August 08, 2023
Find out if AbbVie can overcome sinking sales of its top-selling product.
Via
The Motley Fool
3 Things About Johnson & Johnson Every Smart Investor Knows
↗
July 28, 2023
The company has been a strong value stock but faces big changes this year.
Via
The Motley Fool
3 Biotech Stocks You Better Be Buying on Each and Every Dip
↗
July 27, 2023
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.
Via
InvestorPlace
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
July 21, 2023
From
Genmab A/S
Via
Business Wire
3 Biotech Stocks That AI is Loving in July
↗
July 12, 2023
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.
Via
InvestorPlace
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
↗
July 02, 2023
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
Via
The Motley Fool
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
↗
June 28, 2023
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab...
Via
Benzinga
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
June 27, 2023
From
Genmab
Via
Business Wire
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
June 22, 2023
From
Genmab
Via
Business Wire
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
June 09, 2023
From
Genmab
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
